文献速递类风湿关节炎

多生物标志物疾病活动度评分对起始甲氨蝶呤的类风湿关节炎患者的预测能力、效度和反应性

Predictive ability, validity, and responsiveness of the multi-biomarker disease activity score in patients with rheumatoid arthritis initiating methotrexate.
PubMed 文献 · Semin Arthritis Rheum · 2020-06-17

本研究评估多生物标志物疾病活动度(MBDA)评分在起始甲氨蝶呤的类风湿关节炎(RA)患者中的预测价值、效度和反应性。结果显示基线MBDA评分不能预测ACR反应或低疾病活动度,且MBDA评分与DAS28-ESR等指标相关性弱至中等,对甲氨蝶呤治疗的反应性低于DAS28-ESR。

要点

  • 基线MBDA评分不能预测甲氨蝶呤治疗后的ACR反应或低疾病活动度。
  • MBDA评分与DAS28-ESR和ESR在基线和第16周呈中等至弱相关。
  • MBDA评分对甲氨蝶呤治疗的反应性(SRM 0.71)低于DAS28-ESR(SRM 1.31)。

核心结论

  • MBDA评分不能预测甲氨蝶呤治疗反应,且其反应性低于DAS28-ESR。

研究设计与样本

  • 一项16周开放标签甲氨蝶呤治疗RA研究,纳入130例患者,95例有随访MBDA评分。

主要发现

  • 基线MBDA评分未预测ACR反应或低疾病活动度。
  • 基线DAS28-ESR较高与ACR20反应显著相关(每单位OR 1.89,95%CI 1.20-2.96),但与ACR50、ACR70或低疾病活动度无关。
  • MBDA评分与DAS28-ESR和ESR在基线和第16周呈中等至弱相关,与患者总体和功能呈弱至极弱相关。
  • MBDA评分变化与DAS28-ESR和ESR变化呈中等相关,与患者总体和功能变化呈弱相关。
  • DAS28-ESR的SRM为1.31,MBDA评分的SRM为0.71。

关键数值与推荐

  • 基线DAS28-ESR每单位OR 1.89(95%CI 1.20-2.96)与ACR20反应相关。
  • DAS28-ESR的SRM为1.31,MBDA评分的SRM为0.71。

临床怎么用

  • 在起始甲氨蝶呤的RA患者中,MBDA评分不应用于预测治疗反应。
  • MBDA评分可作为疾病活动度的辅助评估工具,但其反应性低于DAS28-ESR。

局限性

  • 研究为开放标签设计,样本量有限,随访MBDA评分仅95例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/OBJECTIVE: We assessed the predictive value, validity, and responsiveness of the multi-biomarker disease activity (MBDA) score in rheumatoid arthritis (RA) patients initiating methotrexate. METHODS: We examined data from a 16-week, open-label study of methotrexate in RA. Disease activity was assessed and the MBDA score was calculated using serum that was collected and banked from baseline and week 16. Multivariable logistic regression models assessed whether MBDA scores predicted treatment response. Pearson correlations assessed the convergent validity and external responsiveness of the MBDA score with other measures of RA disease activity. Internal responsiveness was assessed by calculating standardized response means (SRMs). RESULTS: A total of 130 patients initiated the study, with follow-up MBDA scores available on 95 patients. Baseline MBDA scores did not predict ACR response or achieving low disease activity. Higher baseline DAS28-ESR scores were significantly associated with an ACR20 response (odds ratio 1.89 per unit, 95% CI 1.20-2.96) but not ACR50, ACR70, or low disease activity. The MBDA score moderate-to-weakly correlated with the DAS28-ESR and ESR at baseline and week 16, with weak-to-very weak correlations with patient global and function. Change in MBDA scores moderately correlated with changes in DAS28-ESR and ESR, while weakly correlating with changes in patient global and function. The DAS28-ESR (SRM 1.31) demonstrated greater responsiveness following methotrexate treatment than the MBDA score (SRM 0.71). CONCLUSIONS: MBDA scores did not predict treatment response to methotrexate. The MBDA score weak-to-moderately correlated with baseline and post-treatment disease activity measures and was less responsive to methotrexate-related improvement than the DAS28-ESR.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Luedders BA, Johnson TM, Sayles H, et al. Predictive ability, validity, and responsiveness of the multi-biomarker disease activity score in patients with rheumatoid arthritis initiating methotrexate. Semin Arthritis Rheum. 2020. PMID: 32911284. doi:10.1016/j.semarthrit.2020.05.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。